Allogene Therapeutics, Inc.
ALLO$184M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO226 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7wMarket Overview
Stock performance and key metrics
ALLO News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Fludarabine
Large B-cell Lymphoma
ALLO-647
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine | Phase 2 | Large B-cell Lymphoma | - | - |
ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply